Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events

S. Hibi, Y. Shirokawa, K. Nanya, Y. Kato, Nobuto Ito, T. Kataoka, T. Yoshida, Yoshiaki Marumo, S. Kayukawa, S. Yuasa, Yoshiteru Tanaka, K. Ina
{"title":"Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events","authors":"S. Hibi, Y. Shirokawa, K. Nanya, Y. Kato, Nobuto Ito, T. Kataoka, T. Yoshida, Yoshiaki Marumo, S. Kayukawa, S. Yuasa, Yoshiteru Tanaka, K. Ina","doi":"10.30683/1927-7229.2021.10.06","DOIUrl":null,"url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) sometimes cause immune-related adverse events (irAEs), the timing of occurrence of which is difficult to predict. We created a system to safely manage the patients treated with ICIs who visit hospital during an emergency. \nMethods: We utilized the Plan-Do-Check-Act (PDCA) cycle method to improve the quality of countermeasures for irAEs in the emergency room. First, an icon showing the patients treated with ICIs was developed for inclusion in electronic medical records. Second, ICI-specified urgent sets of clinical laboratory tests were prepared to cover the spectrum of irAEs. Third, a direct call system to either the attending physician or the chemotherapy team was established. A flow chart for managing irAEs has been prepared since September 2018. We retrospectively analyzed the electronic medical records from September 2018 to December 2020 to determine the effectiveness of the developed system. \nResults: In the first cycle of PDCA, 24 patients administered ICIs were retrospectively surveyed and seven visited the emergency room. Six cases were examined according to the flow chart, whereas the other patient complaining of grade 2 diarrhea were not examined because of incomplete knowledge regarding ICIs and irAEs. As part of the “Act” step, we reminded the doctors of the flow chart and gave a lecture to the residents on how to manage irAEs. During the second and seventh cycle, no cases were observed without consulting the flow chart. \nConclusions: Quality improvement activities for the management of irAEs were conducted using the PDCA cycle methodology. Patients on ICIs are now being continuously monitored to further improve management quality.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Analytical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30683/1927-7229.2021.10.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune checkpoint inhibitors (ICIs) sometimes cause immune-related adverse events (irAEs), the timing of occurrence of which is difficult to predict. We created a system to safely manage the patients treated with ICIs who visit hospital during an emergency. Methods: We utilized the Plan-Do-Check-Act (PDCA) cycle method to improve the quality of countermeasures for irAEs in the emergency room. First, an icon showing the patients treated with ICIs was developed for inclusion in electronic medical records. Second, ICI-specified urgent sets of clinical laboratory tests were prepared to cover the spectrum of irAEs. Third, a direct call system to either the attending physician or the chemotherapy team was established. A flow chart for managing irAEs has been prepared since September 2018. We retrospectively analyzed the electronic medical records from September 2018 to December 2020 to determine the effectiveness of the developed system. Results: In the first cycle of PDCA, 24 patients administered ICIs were retrospectively surveyed and seven visited the emergency room. Six cases were examined according to the flow chart, whereas the other patient complaining of grade 2 diarrhea were not examined because of incomplete knowledge regarding ICIs and irAEs. As part of the “Act” step, we reminded the doctors of the flow chart and gave a lecture to the residents on how to manage irAEs. During the second and seventh cycle, no cases were observed without consulting the flow chart. Conclusions: Quality improvement activities for the management of irAEs were conducted using the PDCA cycle methodology. Patients on ICIs are now being continuously monitored to further improve management quality.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
计划-执行-检查-行动循环在管理免疫相关不良事件中的应用
背景:免疫检查点抑制剂(ICIs)有时会引起免疫相关不良事件(irAEs),其发生时间难以预测。我们创建了一个系统,以安全管理在紧急情况下就诊的接受过ICIs治疗的患者。方法:采用计划-执行-检查-行动(PDCA)循环方法,提高急诊室irae对策的质量。首先,开发了一个显示接受ICIs治疗的患者的图标,以便纳入电子医疗记录。第二,编制了国际传染病研究所指定的紧急临床实验室检测试剂盒,以涵盖各种放射性放射物。第三,建立了直接呼叫主治医生或化疗小组的系统。自2018年9月以来,已编制了管理经济评估机构的流程图。我们回顾性分析了2018年9月至2020年12月的电子病历,以确定所开发系统的有效性。结果:在PDCA的第一个周期中,回顾性调查了24例使用ICIs的患者,其中7例就诊于急诊室。6例患者根据流程图进行检查,而另1例患者因对ICIs和irae的认识不完全,未进行2级腹泻检查。作为“行动”步骤的一部分,我们提醒医生注意流程图,并向住院医生讲授如何管理irae。在第二个和第七个周期中,未参照流程图未观察到任何病例。结论:采用PDCA循环方法进行了irae管理的质量改进活动。目前正在持续监测使用综合免疫系统的患者,以进一步提高管理质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
New Insights on Hyperbaric Oxygen Therapy for Cancer Chemically Induced Brain Cancer in Sprague-Dawley Rats: Changed Lipidomics Mimics the Human Conditions Multiple Primary Malignant Tumours Magnetotherapy in Experimental and Clinical Neuro-Oncology: A Review Uterine Metastasis from Carcinoma of Breast – A Systematic Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1